Change in quality of life, enjoyment, and satisfaction total score with CAPLYTA1

Monotherapy: Q-LES-Q-SF total score at week 6*

This graph depicts the change in quality of life as measured by Q-LES-Q-SF total score at 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy.
This graph depicts the change in quality of life as measured by Q-LES-Q-SF total score at 6 weeks for patients receiving CAPLYTA 42 mg or placebo as monotherapy.

Limitation: This secondary endpoint was not powered for statistical comparison and is descriptive only. Therefore, the results require cautious interpretation.

CAPLYTA 42 mg (n=169)
Placebo (n=164)

Limitation: This secondary endpoint was not powered for statistical comparison and is descriptive only. Therefore, the results require cautious interpretation.

LSM=least squares mean; Q-LES-Q-SF=Quality of Life Enjoyment and Satisfaction Questionnaire—Short Form.

*The Q-LES-Q-SF (Endicot et al, 1993) is a patient-reported, 14-item questionnaire that uses a 5-point rating scale from very poor to very good to assess patient satisfaction with a variety of items. Scores are summed to provide a raw total score ranging from 14 to 70; the total raw score is converted to a percent score.1 Baseline scores were 37.03 for CAPLYTA and 38.61 for placebo.

See consistent safety data across trials

Reference: 1. Data on File. 2021.